0003	Regular blood and urine checks are essential.
0008	Pregnancy must be excluded prior to administration of this drug.
0009	The myocardial depressant effects of this drug and of beta-blocking drugs are additive.
0010	This drug is a potent teratogen-pregnancy should be avoided for at least two years after cessation of therapy.
0011	Flecainide acetate should be avoided in patients with poor cardiac function.
0014	This drug should not be used during pregnancy as it may result in feminisation of the male foetus.
0015	This drug causes birth defects. Isotretinoin has been reported to cause other frequent and potentially serious toxicity.
0017	The risk of drug dependence is high.
0018	Neutropenia and agranulocytosis are more frequent in the elderly, especially in the early months of therapy.
0019	There are concerns about the incidence of benign intracranial hypertension associated with this drug.
0032	Severe thrombocytopenia has been reported with this drug.
0039	Because of variable effects of food on absorption of sustained release theophylline preparations, patients stabilised on one brand should not be changed to another without appropriate monitoring.
0043	There is an increased risk of severe adverse reactions with this combination in the elderly.
0046	For the short-term treatment of localised infective eczema only.
0067	Severe neutropenia is common in the early months of therapy. Haematological monitoring should be undertaken at commencement and every two weeks in the first four months of therapy.
0068	Severe cholestatic hepatitis has been reported with this drug. Significant risk factors are age, particularly greater than 55 years, and duration of treatment longer than 14 days.
0069	Sulfonylureas may cause hypoglycaemia, particularly in the elderly.
0073	Serum electrolytes should be checked regularly.
0074	Use of ACE inhibitors during pregnancy is contraindicated since these drugs have been associated with foetal death in utero.
0075	This drug is an irreversible monoamine oxidase inhibitor.
0076	Nitrofurantoin may cause peripheral neuritis and severe pulmonary reactions.
0077	Hepatotoxicity has been reported with this drug.
0078	Prochlorperazine may be associated with parkinsonism and tardive dyskinesia and should be used for short-term treatment only.
0082	The listed brands have NOT been shown to be bioequivalent and should not be interchanged.
0083	Sumatriptan is contraindicated in patients with known or suspected coronary artery disease. The drug should not be used within 24 hours of ergotamine or dihydroergotamine use.
0088	Zolmitriptan is contraindicated in patients with known or suspected coronary artery disease. The drug should not be used within 24 hours of ergotamine or dihydroergotamine use.
0089	Serum sickness-like reactions have been reported with this drug, especially in children.
0090	Naratriptan is contraindicated in patients with known or suspected coronary artery disease. The drug should not be used within 24 hours of ergotamine or dihydroergotamine use.
0091	Visual field defects have been reported with this drug.
0092	Naltrexone hydrochloride is contraindicated in patients receiving opioid drugs.
0094	Leflunomide is a category X drug and must not be given to pregnant women. Pregnancy should be avoided for two years after cessation of therapy, unless special wash-out procedures are carried out.
0097	Treatment with interferon alfa has been associated with depression and suicide in some patients. Patients with a history of suicidal ideation or depressive illness should be warned of the risks. Psychiatric status during therapy should be monitored.
0099	Abuse of clonazepam has been reported. Refer to the current product information.
0101	Treatment with peginterferon alfa has been associated with depression and suicide in some patients. Patients with a history of suicidal ideation or depressive illness should be warned of the risks. Psychiatric status during therapy should be monitored.
0102	Amiodarone hydrochloride has been reported to cause frequent and potentially serious toxicity. Regular monitoring of hepatic and thyroid function is recommended.
0103	Regular monitoring of drug serum levels is recommended.
0104	Careful monitoring of patients is mandatory.
0105	Bosentan monohydrate is a category X drug and must not be given to pregnant women.  Pregnancy must be avoided during treatment and for at least 3 months following cessation of treatment with this drug.
0107	In placebo controlled trials in elderly patients with dementia there was a significantly higher incidence of cerebrovascular adverse events, such as stroke (including fatalities) and transient ischaemic attacks, in patients treated with risperidone compared with patients treated with placebo.
0108	Thalidomide is a category X drug and must not be given to pregnant women.  Pregnancy in female patients or in the partners of male patients must be avoided during treatment and for 1 month after cessation of treatment.
0109	Appropriate contraceptive measures should be taken by women of child-bearing age in whom spironolactone therapy has been initiated.
0110	There are reports of fatal hepatotoxicity, particularly in children. There is increasing evidence of dose-related teratogenesis from this drug.
0111	The myocardial depressant effects of verapamil hydrochloride and of beta-blocking drugs are additive.
0113	Episodes of sudden onset of sleep without warning, during activity, have been reported with this drug.
0115	Ambrisentan is a category X drug and must not be given to pregnant women.  Pregnancy must be avoided during treatment and for at least 3 months following cessation of treatment with this drug.
0117	Rizatriptan is contraindicated in patients with known or suspected coronary artery disease. The drug should not be used within 24 hours of ergotamine or dihydroergotamine use.
0118	Progressive multifocal leukoencephalopathy has been reported with this drug.
0119	EpiPen and Anapen products have different administration techniques and should not be prescribed to the same patient without training in their use.
0120	Eletriptan is contraindicated in patients with known or suspected coronary artery disease.  The drug should not be used within 24 hours of ergotamine or dihydroergotamine use.
0121	Buprenorphine with naloxone soluble film and buprenorphine with naloxone sublingual tablet do not meet all the criteria for bioequivalence. Patients being switched between sublingual tablets and soluble films may therefore require a dosage adjustment.
0122	Pharmaceutical benefits containing docetaxel may have different concentrations.
0123	Pharmaceutical benefits containing gemcitabine may have different concentrations.
7776	Careful monitoring of patients is mandatory.
8032	Pharmaceutical benefits containing docetaxel may have different concentrations.
8211	The risk of drug dependence is high.
8212	This formulation contains preservative and must not be administered via epidural or intrathecal route.
8357	Treatment with peginterferon alfa has been associated with depression and suicide in some patients. Patients with a history of suicidal ideation or depressive illness should be warned of the risks. Psychiatric status during therapy should be monitored.
8358	Ribavirin is a category X drug and must not be given to pregnant women. Pregnancy in female patients or in the partners of male patients must be avoided during treatment and during the 6 months period after cessation of treatment.
9216	Monitor for post-injection syndrome for at least two hours after each injection.
9409	Teriflunomide is a category X drug and must not be given to pregnant women or women of childbearing potential who are not currently using reliable contraception. Pregnancy should be avoided for two years after cessation of therapy, unless special wash-out procedures are carried out. 
